Metabolomic Profiling of Patients With Traumatic Brain Injury
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorDr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
About this trial
Traumatic Brain Injury (TBI) is a significant cause of mortality and morbidity worldwide. However, the literature on determining its severity and predicting prognosis is insufficient. This study aimed to examine the differences in metabolite levels between trauma patients with severe TBI and orthopedic trauma patients without brain injury.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Ages 18-65
Patients diagnosed with severe TBI clinically or according to National Institute for Health and Care Excellence (NICE) criteria (including post-traumatic imaging)
Patients with non-TBI orthopedic or multitrauma
Disqualifiers
Presence of brain pathology in the pre-trauma period
Patient with chronic subdural hematoma
Trial population
Trauma patients with or without TBI, aged between 18 and 65 years, who applied to Aksaray UniversityTraining and Research Hospital will be included in the study.
Trial design
Design model
Other
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
60 Participants
are grouped into 2 trial groupsGroup A: TBI
Group B: Non_TBI
Trial outcomes
Primary outcomes
1
metabolomic analysis
Venous blood samples are taken from the participants after the injury. Samples will be analysed using LC/MS. All relevant metabolomes and their respective metabolic pathways will be evaluated using the "KEGG Pathway database".
Time frame
Day 1Locations
1Map coordinates are unavailable for these locations. Locations are shown below instead.
Aksaray UniversityRecruiting06810, Aksaray, AnkaraTurkey (Türkiye)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
Lead sponsor
Aksaray University Training and Research Hospital
Sponsor institution
Source ClinicalTrials.gov